Market Cap : 3.75 B | Enterprise Value : 4.16 B | PE Ratio : At Loss | PB Ratio : 7.03 |
---|
NAS:GH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:GH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Guardant Health's Revenue for the three months ended in Mar. 2022 was $96.1 Mil. Guardant Health's Total Assets for the quarter that ended in Mar. 2022 was $2,167.0 Mil. Therefore, Guardant Health's Asset Turnover for the quarter that ended in Mar. 2022 was 0.04.
Asset Turnover is linked to ROE % through Du Pont Formula. Guardant Health's annualized ROE % for the quarter that ended in Mar. 2022 was -83.68%. It is also linked to ROA % through Du Pont Formula. Guardant Health's annualized ROA % for the quarter that ended in Mar. 2022 was -22.75%.
The historical data trend for Guardant Health's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asset Turnover measures how quickly a company turns over its asset through sales.
Guardant Health's Asset Turnover for the fiscal year that ended in Dec. 2021 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (A: Dec. 2021 ) | / | ( (Total Assets (A: Dec. 2020 ) | + | Total Assets (A: Dec. 2021 )) | / count ) |
= | 373.653 | / | ( (2271.781 | + | 2204.499) | / 2 ) |
= | 373.653 | / | 2238.14 | |||
= | 0.17 |
Guardant Health's Asset Turnover for the quarter that ended in Mar. 2022 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (Q: Mar. 2022 ) | / | ( (Total Assets (Q: Dec. 2021 ) | + | Total Assets (Q: Mar. 2022 )) | / count ) |
= | 96.099 | / | ( (2204.499 | + | 2129.598) | / 2 ) |
= | 96.099 | / | 2167.0485 | |||
= | 0.04 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Asset Turnover is linked to ROE % through Du Pont Formula.
Guardant Health's annulized ROE % for the quarter that ended in Mar. 2022 is
ROE %** | (Q: Mar. 2022 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | -492.912 | / | 589.0225 | ||
= | (Net Income / Revenue) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (-492.912 / 384.396) | * | (384.396 / 2167.0485) | * | (2167.0485/ 589.0225) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | -128.23 % | * | 0.1774 | * | 3.6791 |
= | ROA % | * | Equity Multiplier | ||
= | -22.75 % | * | 3.6791 | ||
= | -83.68 % |
Note: The Net Income data used here is four times the quarterly (Mar. 2022) net income data. The Revenue data used here is four times the quarterly (Mar. 2022) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Guardant Health's annulized ROA % for the quarter that ended in Mar. 2022 is
ROA % | (Q: Mar. 2022 ) | ||
= | Net Income | / | Total Assets |
= | -492.912 | / | 2167.0485 |
= | (Net Income / Revenue) | * | (Revenue / Total Assets) |
= | (-492.912 / 384.396) | * | (384.396 / 2167.0485) |
= | Net Margin % | * | Asset Turnover |
= | -128.23 % | * | 0.1774 |
= | -22.75 % |
Note: The Net Income data used here is four times the quarterly (Mar. 2022) net income data. The Revenue data used here is four times the quarterly (Mar. 2022) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Thank you for viewing the detailed overview of Guardant Health's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Talasaz Amirali | director, officer: Chairman, President and COO | 18 ISABELLA AVENUE ATHERTON CA 94027 |
Kaul Samir | director | C/O KHOSLA VENTURES 3000 SAND HILL ROAD, BLDG. 3, SUITE 170 MENLO PARK CA 94025 |
Meresman Stanley J | director | 2071 HUNTINGTON LANE LOS ALTOS CA 94024 |
Svf Bluebird (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Svf Enterprise (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Sb Investment Advisers (uk) Ltd | 10 percent owner | 69 GROSVENOR STREET LONDON X0 W1K 3JP |
Softbank Vision Fund (aiv M1) L.p. | 10 percent owner | 251 LITTLE FALLS DRIVE WILMINGTON DE 19808 |
Svf Endurance (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Clark Ian T | director | SOLAZYME, INC. 225 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080 |
Eltoukhy Helmy | director, officer: Chief Executive Officer | 2 BARRY LANE ATHERTON CA 94027 |
Bertocci Derek A | officer: Chief Financial Officer | 3070 ORCHARD DRIVE SAN JOSE CA 95134 |
Saia John G. | officer: See Remarks | C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY CA 94063 |
Gadde Vijaya | director | C/O TWITTER INC 1355 MARKET STREET SUITE 900 SAN FRANCISCO CA 94103 |
Jallal Bahija | director | 120 MONUMENT CIRCLE INDIANAPOLIS IN 46204 |
Nishar Dipchand | director | C/O LINKEDIN CORPORATION 2029 STIERLIN COURT MOUNTAIN VIEW CA 94043 |
From GuruFocus
Other Sources
By Zacks 2022-01-28
By Fool 2022-03-18
By Zacks 2022-01-26
By Seekingalpha 2021-11-04
By tipranks.com 2022-03-05
By Zacks 2022-01-27
By Zacks 2021-07-30
By Fool 2022-04-01
By Zacks 2021-07-19
By Zacks 2021-11-04
By Seekingalpha 2022-01-03
By Seekingalpha 2022-01-24